SB1317
CAS号 | 1204918-72-8 | 货号 | BCP42651 |
中文名 | SB1317 | ||
英文名 | SB1317 | ||
中文别名 | |||
英文别名 | Ex45; Ex-45; EX 45; TG02; TG 02; TG02; SB1317; SB 1317; Zotiraciclib; | ||
分子式 | C23H24N4O | 分子量 | 372.46 |
生物活性 | SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. SB1317 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. In vivo, SB1317 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. SB1317 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). SB1317 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias. | ||
上下游产品 | 937270-47-8(SB-1317) | ||
信号通路 | Angiogenesis/Protein Tyrosine Kinase Cell Cycle/DNA Damage Jak/Stat Pathway Wnt/Stem Cell Epigenetics | ||
靶 点 | FLT3 JAK CDK |
结构式
本页面部分数据来自于公开的网络资源,所以瀚香生物不能保证其准确性。
不同批次的产品详情请咨询我们的客服:
- 全国免费电话:400-099-8200
瀚香生物(Biochempartner) 的所有产品和服务仅用于科学研究,禁止用于人体和治疗!